Wearable cuffless blood pressure monitor to guide care in uncontrolled hypertension
Tests a wearable cuffless monitor to guide treatment in adults with uncontrolled hypertension.
Plain-language title generated from the registry record
Registry title: CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension
Key facts
- Where
- Ansan and Seoul, South KoreaSee the 3 sites
Where in South Korea
- Korea University Ansan HospitalAnsan, South KoreaTaking people
- Korea University Anam HospitalSeoul, South KoreaTaking people
- Korea University Guro HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Korea University Anam Hospital
- Trial code
- NCT07465549
- Record updated
- 30 April 2026
- Original description
This multicenter, prospective, open-label randomized controlled trial evaluates the efficacy and safety of CART BP Pro-guided blood pressure management in Korean patients with uncontrolled hypertension. CART BP Pro is a wearable cuffless blood pressure monitoring device based on photoplethysmography technology that enables continuous ambulatory blood pressure monitoring.Read full original descriptionShow less
Efficacy and Safety of Cuffless Ambulatory Blood Pressure Monitoring Device-Guided Blood Pressure Management Compared With Usual Care in Korean Patients With Uncontrolled Hypertension: A Multicenter Prospective Randomized Controlled Trial
This multicenter, prospective, open-label randomized controlled trial evaluates the efficacy and safety of CART BP Pro-guided blood pressure management in Korean patients with uncontrolled hypertension. CART BP Pro is a wearable cuffless blood pressure monitoring device based on photoplethysmography technology that enables continuous ambulatory blood pressure monitoring.
Eligible participants with uncontrolled hypertension despite ongoing antihypertensive therapy will be randomly assigned in a 1:1 ratio to either a CART BP Pro-guided management group or a usual care group based on conventional office blood pressure measurements. Antihypertensive treatment in both groups will follow guideline-based therapy using standard agents including angiotensin receptor blockers, calcium channel blockers, and thiazide diuretics.
The primary efficacy endpoint is the between-group difference in 24-hour mean systolic blood pressure at 24 weeks measured using ambulatory blood pressure monitoring. Safety will be assessed by the incidence of treatment-emergent adverse events during the study period.
Inclusion: Age ≥ 19 years; Uncontrolled hypertension defined as office systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; Ability and willingness to provide written informed consent and comply with study procedures.
Exclusion: History of intolerance or contraindication to olmesartan, amlodipine, or hydrochlorothiazide; Suspected secondary hypertension; Any serious medical condition that may interfere with study participation or interpretation of study results; Atrial fibrillation; Pregnancy or lactation.